Georges van Baelen, MScPh

Georges van Baelen, MScPh studied Medical and Pharmaceutical Sciences at the “Katholieke Universiteit Leuven KUL” and the “Université Catholique de Louvain UCL”, in Belgium and did doctoral work in Toxicology and Advanced Pharmacology at the Joint Graduate Program at Rutgers University / Robert Wood Johnson Medical School UMDNJ in New Jersey, USA. He also obtained certification in Latin American Pharmacovigilance Practices from the University of Antioquia in Medellín, Colombia. He was a key person in the management and oversight of the OPTIME trial before becoming a Director of Cardiology at United Health, where he participated in publication planning and authoring of several articles on heart disease and its therapies. As Global Director of Pharmacovigilance at AXA, Mr. van Baelen built globally integrated Pharmacovigilance Systems in Europe, Latin America and Australia, while overseeing Global Medical Information Services for various biotechnology and pharmaceutical companies. Mr. van Baelen is currently Founder and President of Arctiryon, Inc., headquartered in Chicago, USA, and travels extensively throughout Latin America, advising and assisting US and EU-based clients with the pharmaceutical regulations of Central and South American countries, as well as many European Union members. He resides part-time in Brazil and part-time in the United States.